Infectious disease news - the latest biotech news from Labiotech.eu

Home Infectious disease Page 18

Latest Posts

aspergillosis aspergillus mathias eu pet mri

News and Trends 23 Feb 2016

This new Antibody-based Imaging Technology could help fight Deadly Fungal Infections

It is estimated that up to 200,000 people globally die from fungal lung infections (Aspergillosis). Now, the EU-funded Fp7 MATHIAS project has developed an imaging technique to help doctors fight this huge killer of patients with weakened immune systems. The new test involves attaching radioactively labelled antibodies to the infecting structures formed by the fungus Aspergillus fumigatus. These fungal spores […]

February 23, 2016 - 3 minutesmins - By Dani Bancroft

gilead hiv aids grant retroviral truvada

News and Trends 23 Feb 2016

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

The US Giant Gilead is opening a new program of Grants to fund the next generation of HIV research for 3-years. Targets are academic institutions and non-profit organization. HIV remains a global health challenge, with around 37 million people infected in the world. The rate of new infections fell in the last decades, but it is […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

zimmerman aicuris labiotech s

News and Trends 15 Feb 2016

Celebrating the 10th Birthday of this German Infectious Disease Biotech with the CEO

AiCuris is a Biotech company based on the Bayer Life Sciences park in Wuppertal (Germany). It is working on new anti-infective drugs and is a former spin-off of Germany’s biggest Pharma Company. It’s celebrating its 10th birthday this year, which is good reason to interview the CEO… So AiCuris is working on anti-infective drugs for […]

February 15, 2016 - 4 minutesmins - By Philip Hemme

Moustique tigre 744x348

News and Trends 4 Feb 2016

Zika Virus: Who in Biotech is Working to Stop its Spread?

The Zika virus epidemic could infect up to 4 Million people. As a cousin to Dengue Fever, what are the risks? Who in the Biotech and pharma world are working on a vaccine? And what is exactly this virus which has everyone hot and bothered? Literally meaning ‘overgrown‘ in the Luganda language, the Zika Virus name comes from the […]

February 4, 2016 - 4 minutesmins - By Nicolas Sainte-Foie

pei ying lin smallpox syndrome bioart uk

News and Trends 29 Jan 2016

Pei-Ying Lin’s BioArt: Stunning Smallpox, Nutritious NanoFood and Microbial Fractals

Pei-Ying Lin founded the Taiwanese BioArt community with her Science-Humanities and programming background to tackle complex BioArt statements all across the EU. Lin is a Scientist-turned-artist, with her fascination in BioArt having stemmed from a Life Sciences degree from the National Tsing Hua University in Taiwan and a Masters at the Royal College of Art in London. She’s also […]

January 29, 2016 - 2 minutesmins - By Dani Bancroft

genticel hpv neoplasm phase II fail

News and Trends 28 Jan 2016

Viral Immunotherapy Trial Failure Causes French Biotech Stocks to Drop 43%

Genticel (France) is a clinical biotech developing a cervical cancer immunotherapy against the Human papillomavirus. However, their 24-month phase II trial has failed to meet primary endpoint at its halfway point, and their stocks dropped 43% overnight. Around 70% of cervical cancer cases are caused by 2 types of Human papillomavirus (HPV): 16 and 18. And among the 300 million women around the […]

January 28, 2016 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT

kuros cytos biotechnologies biosciences vaccine hepatitis merger bone biosurgeries

News and Trends 20 Jan 2016

Swiss Biotech Merger: Bones + Oncology + Vaccines?

Kuros Biosurgery in Zürich (Switzerland), the bone remodelling biotech for trauma patients, today officially acquired Cytos Biotechnology in Schlieren, the two of which are now to be rebranded ‘Kuros Biosciences’ in a Swiss Stock Exchange merger. Kuros is developing innovative products for tissue repair and regeneration. The company is a spin-off of the Swiss Federal […]

January 20, 2016 - 2 minutesmins - By Dani Bancroft

avian influenza flu bird pandemic nature host imperial

News and Trends 14 Jan 2016

Angry birds: How does Avian Influenza Virus infect Human cells?

What does the bird flu virus have to change in order to takeover the human cell machinery? For the first time, researchers from Imperial College London have identified the pathway that allows Avian flu virus to hop from bird’s to mammalian cells. Influenza pandemics aren’t easy to predict: outbreaks occur when zoonotic influenza viruses suddenly […]

January 14, 2016 - 3 minutesmins - By Lourdes Riquelme

HIV abivax Alexey Kashpersky abx464 trial antiviral

News and Trends 13 Jan 2016

A Phase II HIV Antiviral from France Has Promising Results

Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy for patients with HIV infection, which could potentially take a corner in an annual $18Bn market. HIV and AIDs have a long-standing history (the quick – yet fascinating story of which can be read here), and since 1983 (when the […]

January 13, 2016 - 3 minutesmins - By Dani Bancroft

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

bacteria neutrophil immune response RNA

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

ablynx antibodies rsv infection nanobody llama

News and Trends 18 Dec 2015

64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies Will Save Infant Lives

Ablynx, the Alpaca Nanobody Biotech from Belgium, has completed target enrollment of the first-in-infant Phase I/IIa study with its anti-Respiratory Syncytial virus, which is linked to 3,000-8,500 infant deaths each year. ALX-0171 is a wholly-owned Nanobody drug candidate administered through inhalation (nebulisation), for the treatment of respiratory syncytial virus (RSV) infection in infants. The candidate […]

December 18, 2015 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT